Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · May 7, 2009

Keywords

ClinConnect Summary

This is an observational research study at the NIH Clinical Center that aims to learn more about immune system disorders by studying the biology of skin and other cells. Researchers will collect small skin samples (and nasal cells) from people with immune problems and from healthy volunteers. They will grow skin cells (fibroblasts) from these samples and may turn some into stem-like cells for lab research. The goal is to understand genetic and cellular features of immune diseases, not to test a treatment.

Who can join: People aged 2 to 85 with a known immune system disorder (such as primary immunodeficiency or immune dysregulation) or who are a biological relative of someone with such a condition. Healthy volunteers aged 18 to 85 who are already part of related NIH studies can also participate. Participants may have up to two small punch skin biopsies taken under local anesthesia, and nasal cell samples may be collected. The study plans to enroll about 200 people over about 15 years. Results aren’t returned to participants, and data aren’t shared back as individual findings. This study is not a drug or device trial and is conducted at the NIH Clinical Center in Bethesda, Maryland.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• Patients:
• • 1. To be enrolled in this study, a patient must be \>=2 years of age but not \>85 years of age,
• • 2. have a known diagnosis of primary immunodeficiency or immunodysregulation (or be a blood relative of such as patient),
• • 3. be concurrently enrolled on an NIH IRB approved NIAID protocol that includes genetic testing for disease of the immune system, such as but not limited to 05-I-0213 or 06-I-0015
• Patient Relative: To be enrolled in this study, a patient relative must be:
• • 1. A biological relative of a participant being studied under this protocol. Relatives may be biological mother, father, sibling, children, grandparents, aunts, uncles and first cousins.
• • a. A minor relative of the proban participant must demonstrate that they are asymptomatic carriers or are at risk for the disease
• • 2. be concurrently enrolled on an NIH IRB approved protocol that includes genetic testing for disease of the immune system, such as but not limited to 05-I-0213 or 06-I-0015.
• • 3. Greater than or equal to 8 years of age but not greater than 85 years of age,
• Healthy Volunteers:
• To be enrolled in this study, a normal volunteer must fulfill all of the following criteria:
• • 1. Be enrolled on protocol 05-I-0213.
• • 2. Be a healthy adult of either sex and between ages of 18 years and 85 years
• EXCLUSION CRITERIA:
• Patients or the Patient Relative are not eligible to be in this trial if::
• • 1. Platelet count less than 20,000/microL
• • 2. The individual is hemodynamically unstable because of acute bleeding.
• • 3. Any condition that, in the investigator s opinion, places the patient at undue risk by participating in the study or limits the utility of the specimen to be obtained.
• • 4. For Nasal Scraping: a history of turbinectomy or significant nasal pathology that would preclude obtaining mucosal scrape biopsies.
• A Healthy Volunteer is not eligible to be in this trial if they:
• • 1. Areless than 18 years old or older than 85 years
• • 2. Weighs less than 110 pounds
• • 3. Are pregnant or breastfeeding
• • 4. Are receiving a chemotherapeutic agent(s) or has a malignancy
• • 5. Cannot avoid taking aspirin or non-steroidal anti-inflammatory medications during the 7 days preceding skin biopsy
• • 6. Have history of heart, lung, kidney disease, bleeding disorders, diabetes mellitus, chronic peripheral arterial or venous insufficiency, chronic diffuse skin conditions without uninvolved areas suitable for skin biopsy, poor skin healing, or keloid formation.
• • 7. Have been diagnosed as having viral hepatitis (B or C), human immunodeficiency virus (HIV), or a carrier for methicillin-resistant Staphylococcus aureus (MRSA)
• • 8. Hemoglobin measurement is less than 12.0 g/dL
• • 9. Platelet count less than 150,000/(micro)L
• • 10. PT greater than 15.0 seconds or PTT greater than 40 seconds
• • 11. Have a history of intravenous injection drug use or of engaging in high-risk activities for exposure to the acquired immunodeficiency syndrome (AIDS) virus.